Multiple myeloma, also known as myeloma, is the third most common hematologic cancer (cancer of the blood). However, compared to more frequently occurring cancers (e.g., breast, prostate, lung, and colorectal cancers), multiple myeloma is relative rare and accounts for only 1.6 percent of diagnoses each year. For 2018, the American Cancer Society estimates that 30,770 new cases of myeloma will be diagnosed in the U.S.1 Due to the less common occurrence of multiple myeloma, providers are less likely to diagnosis and treat these patients on a regular basis.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68:7-30.
ACCC is conducting this education program to understand how the current dispensing landscape is affecting delivery of oral therapies for patients with multiple myeloma. To better understand the impact on providers and patients, ACCC is conducting a series of focus group discussions.
Three specialists in multiple myeloma care share their experiences that may help other providers and patients move smoothly through this time of transition while maintaining high quality care.
Learn how to identify key disparities in clinical trial access for patients with multiple myeloma and explore strategies that can help improve access for underserved communities. (October 21, 2020)
Effective communication with patients is key to providing optimal care to patients. Learn the most effective strategies for successful conversation with patients undergoing treatment for multiple myeloma and discover valuable resources that can help.
Expert faculty will Identify new emerging therapies in the care for multiple myeloma patients and provide examples of how to operationalize care of this patient population.
Learn how to better identify and utilize financial resources that are available for patients with multiple myeloma, and implement strategies to improve insurance verification procedures.
Causes, risk factors, and prevention vary among cancer types, and multiple myeloma presents its own unique risk factors, such as age, gender, race, and family history, among others. Learn about the various precursor conditions for multiple myeloma and how to determine the risk of developing the disease.
COVID-19 has impacted how providers are dispensing multiple myeloma medications and providing care to patients during the pandemic. Learn how to identify those effects to help mitigate them and implement strategies to improve telehealth medicine during the pandemic.
ACCC is committed to help ensure access to recommended care for patients who receive treatment for multiple myeloma or acute lymphoblastic leukemia (ALL) through a partnership with the American Cancer Society and Project ECHO. The educational focus will be on bringing the latest content knowledge and best practices in the treatment of these hematological cancer patients to your cancer care team.
Participation in the TeleECHO Clinic is free. The clinics will convene by videoconference each month.
Each session of the Advances in Multiple Myeloma and Acute Lymphoblastic Leukemia TeleECHO Clinic includes a short talk on a topic related to the treatment of these hematological cancer patients and review of patient cases submitted by spoke site participants. Topics include:
This program will provide specialty multiple myeloma and acute lymphoblastic leukemia cancer treatment information and training to healthcare providers to help build their capacity to provide high-quality, best-practice care locally for patients and thereby increase access to care across the nation.
If you are an ACCC Cancer Program Member and are interested in hosting this live educational program at your site, please contact Janelle Schrag, Assistant Director of Research Programs, Provider Education at ACCC.
Guided by an expert Advisory Committee, this ACCC education project aims to support the multidisciplinary cancer care team in diagnosing, testing, and treating patients with multiple myeloma. This project seeks to:
ACCC's publication, Multidisciplinary Multiple Myeloma Care: Models of Effective Care Delivery, provides a summary of recent updates in myeloma management, along with profiles that describe how three cancer programs—a community-based comprehensive program, an academic medical center, and an NCI-designated program—are delivering multidisciplinary care to this patient population. Plus, access an on-demand lecture series covering topics such effective management of patients with high-risk profiles, summary of guideline recommendations for prevention and management of skeletal-related events, and the importance of the multidisciplinary, team-based approach to care.
The ACCC educational initiative, The Transplant Treatment Path: Optimizing Patient-Centered Care for ASCT in Multiple Myeloma aimed at improving provider communication to optimize the treatment of multiple myeloma patients in the community cancer center pre- and post-autologous stem cell transplant (ASCT).